EUVIMEDEUVIMED entdecken
Leserbrief

Caution in interpreting tralokinumab outcomes in dupilumab nonresponders

Ercan Yılmaz, Erdem Topal, Dursun Turkmen

Journal of the American Academy of Dermatology · 2026-08

DOI: 10.1016/j.jaad.2026.06.150 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Journal of the American Academy of Dermatology, 2026-08. Verfasst von Ercan Yılmaz und 2 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Allergy and Immunology Department, Faculty of Medicine, Inonu University, Malatya, Turkey. Die Arbeit nennt 3 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

atopic dermatitisdupilumabtralokinumab

Autor:innen und Institutionen

  • Pediatric Allergy and Immunology Department, Faculty of Medicine, Inonu University, Malatya, Turkey.
  • Pediatric Allergy and Immunology Department, Faculty of Medicine, Inonu University, Malatya, Turkey. Electronic address: erdemtopal44@gmail.com.
  • Department of Dermatology, Faculty of Medicine, Inonu University, Malatya, Turkey.

Zitieren

APA

Yılmaz, E., Topal, E., & Turkmen, D. (2026). Caution in interpreting tralokinumab outcomes in dupilumab nonresponders. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2026.06.150

Vancouver

Yılmaz E, Topal E, Turkmen D. Caution in interpreting tralokinumab outcomes in dupilumab nonresponders. Journal of the American Academy of Dermatology. 2026. doi:10.1016/j.jaad.2026.06.150

BibTeX
@article{Ylmaz2026,
  author = {Yılmaz, Ercan and Topal, Erdem and Turkmen, Dursun},
  title = {Caution in interpreting tralokinumab outcomes in dupilumab nonresponders},
  journal = {Journal of the American Academy of Dermatology},
  year = {2026},
  doi = {10.1016/j.jaad.2026.06.150}
}
Kostenlos starten →